Award recordCONTRACT

EXCELLIUM PHARMACEUTICAL INC.

PIID VA797P17J0040· VA Staff Offices· NAC PHARMACEUTICALS (36E797)· 6505 · DRUGS AND BIOLOGICALS· FY2017· $78,054 net obligations· UEI LHJYQLD9GCG7· NJ

Description

FINALIZE CLOSURE OF BPA FOR FUROSEMIDE TABLETS

Base award description: FUROSEMIDE TABLETS

First action · last action
2017-03-06 · 2017-07-12
Transactions
2
First transaction's obligation
$79,074
Base + all options value (sum of deltas)
$78,054
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
VA797P16A0022
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 2 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$79,074$0Base award · 2017-03-06 · this action $79,074 · running total $79,074Modification P00001 · 2017-07-12 · this action -$1,020 · running total $78,054
  • Base2017-03-06+$79,074= $79,074
  • Mod P000012017-07-12-$1,020= $78,054
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2017-03-06+$79,074$79,074FUROSEMIDE TABLETS
Mod P00001· FUNDING ONLY ACTION2017-07-12−$1,020$78,054FINALIZE CLOSURE OF BPA FOR FUROSEMIDE TABLETS

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI LHJYQLD9GCG7)

AwardOffice · PSC / listingNet obligationsFY
VA797P17J0054NAC PHARMACEUTICALS 36P797 · 6505 · DRUGS AND BIOLOGICALS$48,519FY2017
VA797P17J0041NAC PHARMACEUTICALS 36P797 · 6505 · DRUGS AND BIOLOGICALS$32,013FY2017
VA797P17J0036NAC PHARMACEUTICALS 36P797 · 6505 · DRUGS AND BIOLOGICALS$29,342FY2017
VA797P17J0035NAC PHARMACEUTICALS 36P797 · 6505 · DRUGS AND BIOLOGICALS$26,827FY2017
VA797P17J0024NAC PHARMACEUTICALS 36P797 · 6505 · DRUGS AND BIOLOGICALS$24,088FY2017
VA797P17J0020NAC PHARMACEUTICALS 36P797 · 6505 · DRUGS AND BIOLOGICALS$39,979FY2017

Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)

AwardRecipientOfficeNet obligationsFY
36E79726A0025CHIESI USA INCNAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0024NEUROTECH PHARMACEUTICALS, INCNAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0023TAKEDA PHARMACEUTICALS AMERICA, INC.NAC PHARMACEUTICALS (36E797)$0FY2026
36E79726D0041GOLDEN STATE MEDICAL SUPPLY, INC.NAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0022AURINIA PHARMA US INCNAC PHARMACEUTICALS (36E797)$0FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA797P17J0040_3600_VA797P16A0022_3600 · retrieved 2026-09-26.